ATE447005T1 - Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz - Google Patents

Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz

Info

Publication number
ATE447005T1
ATE447005T1 AT98946891T AT98946891T ATE447005T1 AT E447005 T1 ATE447005 T1 AT E447005T1 AT 98946891 T AT98946891 T AT 98946891T AT 98946891 T AT98946891 T AT 98946891T AT E447005 T1 ATE447005 T1 AT E447005T1
Authority
AT
Austria
Prior art keywords
genetically modified
modified tumor
targeted bacteria
tumor targeted
reduced virulence
Prior art date
Application number
AT98946891T
Other languages
English (en)
Inventor
David Bermudes
Kenneth Low
Martina Ittensohn
Original Assignee
Vion Pharmaceuticals Inc
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vion Pharmaceuticals Inc, Univ Yale filed Critical Vion Pharmaceuticals Inc
Priority claimed from PCT/US1998/018701 external-priority patent/WO1999013053A1/en
Application granted granted Critical
Publication of ATE447005T1 publication Critical patent/ATE447005T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/879—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98946891T 1997-09-10 1998-09-09 Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz ATE447005T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/926,636 US6080849A (en) 1997-09-10 1997-09-10 Genetically modified tumor-targeted bacteria with reduced virulence
US09/149,832 US6447784B1 (en) 1997-09-10 1998-09-08 Genetically modified tumor-targeted bacteria with reduced virulence
PCT/US1998/018701 WO1999013053A1 (en) 1997-09-10 1998-09-09 Genetically modified tumor-targeted bacteria with reduced virulence

Publications (1)

Publication Number Publication Date
ATE447005T1 true ATE447005T1 (de) 2009-11-15

Family

ID=25453492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98946891T ATE447005T1 (de) 1997-09-10 1998-09-09 Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz

Country Status (5)

Country Link
US (5) US6080849A (de)
KR (1) KR20010015577A (de)
AT (1) ATE447005T1 (de)
DE (1) DE69841261D1 (de)
ZA (1) ZA988289B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997881A (en) * 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6207648B1 (en) * 1997-07-24 2001-03-27 Trustees Of Boston University Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
EP1261369A4 (de) * 1999-10-04 2006-02-01 Vion Pharmaceuticals Inc Verbindungen und methoden zum tumorgerichteten transport von effektormolekülen
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
CA2342040C (en) * 2000-09-21 2012-07-10 Kyowa Hakko Kogyo Co., Ltd. Anaerobic bacterium as a drug for cancer gene therapy
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
US7396822B2 (en) 2001-05-24 2008-07-08 Vaxiion Therapeutics, Inc. Immunogenic minicells and methods of use
EP1281767A3 (de) 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US7015027B1 (en) 2001-11-20 2006-03-21 Mds (Canada) Inc. Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
US20030224369A1 (en) * 2002-02-25 2003-12-04 Surber Mark W. Reverse screening and target identification with minicells
US20030224444A1 (en) * 2002-02-25 2003-12-04 Sabbadini Roger A. Antibodies to native conformations of membrane proteins
US20030207833A1 (en) * 2002-02-25 2003-11-06 Neil Berkley Pharmaceutical compositions with minicells
US20040005700A1 (en) * 2002-05-28 2004-01-08 Surber Mark W. Poroplasts
EP1369491A1 (de) * 2002-06-05 2003-12-10 Aladar A. Szalay Lichtemittierende Mikroorganismen und Zellen für die Diagnose und Therapie von Krankheiten assoziiert mit Wunden oder entzündetem Gewebe
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
ATE545699T1 (de) 2003-06-18 2012-03-15 Genelux Corp Modifizierte, rekombinante vacciniaviren und deren verwendungen
EP1654364A4 (de) * 2003-08-13 2008-02-13 Novartis Vaccines & Diagnostic Zuführung von immungene codierenden polynukleotiden an inakivierte wirtszellen
US7390646B2 (en) * 2003-09-17 2008-06-24 The Regents Of The University Of California Bacterial vectors and methods of use thereof
US20050112097A1 (en) * 2003-11-26 2005-05-26 Hinton Golden S. Method for the treatment of cancer
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules
WO2006055024A2 (en) * 2004-04-05 2006-05-26 Vaxiion Therapeutics, Inc. Minicells as vaccines
US20050244375A1 (en) * 2004-04-29 2005-11-03 Leonard Arnold S Composition and method of cancer treatment
JP4926061B2 (ja) 2004-05-21 2012-05-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア イソプレノイド化合物の産生を促進する方法
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
PT2088193E (pt) 2004-11-24 2011-02-24 Anaeropharma Science Inc Novo vector vaivém
CN101155911B (zh) * 2005-04-08 2015-08-26 阿内罗药物科学株式会社 5-氟尿嘧啶耐受菌及其制备方法
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
CA2613469C (en) 2005-07-05 2014-08-12 The Regents Of The University Of California Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof
EP2027272B1 (de) * 2006-05-24 2016-01-06 Scarab Genomics, LLC Plasmid-dna-zubereitungen und verfahren zu ihrer herstellung
KR101417146B1 (ko) 2006-05-26 2014-07-08 아미리스 인코퍼레이티드 이소프레노이드의 생산 방법
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
EP2066778B1 (de) 2006-09-26 2016-01-27 The Regents of The University of California Herstellung von isoprenoiden und isoprenoidvorläufern
US7998461B2 (en) * 2007-11-15 2011-08-16 University Of Massachusetts Salmonella cancer therapeutics and related therapeutic methods
EP2242516A1 (de) * 2008-01-11 2010-10-27 Genelux Corporation Verfahren und zusammensetzungen zum nachweis von bakterien und zur behandlung von erkrankungen und störungen
US8647642B2 (en) * 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2010151609A1 (en) * 2009-06-24 2010-12-29 Photoswitch Biosciences Inc. Photoswitch-enabled ion channel assay system
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011143124A2 (en) 2010-05-10 2011-11-17 The Regents Of The University Of California Endoribonuclease compositions and methods of use thereof
WO2012008860A2 (en) 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto
AU2012217728B2 (en) 2011-02-15 2017-04-27 Vaxiion Therapeutics, Llc Therapeutic compositions and methods for antibody and Fc-containing targeting molecule-based targeted delivery of bioactive molecules by bacterial minicells
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013090356A2 (en) 2011-12-16 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
WO2013128288A1 (en) * 2012-02-27 2013-09-06 Thelial Technologies S.A. Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US9127284B2 (en) 2012-05-04 2015-09-08 The University Of Hong Kong Modified bacteria and their uses thereof for the treatment of cancer or tumor
JP6578206B2 (ja) 2012-07-19 2019-09-18 レッドウッド バイオサイエンス， インコーポレイテッド Ｃｄ２２に特異的な抗体およびその使用方法
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EA039554B1 (ru) 2013-06-10 2022-02-09 АйПИЕРИАН, ИНК. Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
CN106459138A (zh) 2014-03-28 2017-02-22 斯坦福大学托管董事会 工程化的光激活阴离子通道蛋白及其使用方法
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
KR102894634B1 (ko) 2015-03-31 2025-12-02 소흠, 인코포레이티드 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템
IL318523A (en) 2015-04-06 2025-03-01 Bioverativ Usa Inc Human anti-C1S antibodies and methods of using them
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PL3344654T3 (pl) 2015-09-02 2021-05-17 Immutep S.A.S. Przeciwciała anty-lag-3
CN116790614A (zh) 2016-04-04 2023-09-22 比奥贝拉蒂美国公司 抗补体因子bb抗体以及其用途
JP7069138B2 (ja) 2016-10-12 2022-05-17 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗Ｃ１ｓ抗体およびその使用方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3998336B1 (de) 2017-04-27 2026-01-07 The Regents of The University of California Mikroorganismen und verfahren zur herstellung von cannabinoiden und cannabinoidderivaten
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
WO2019075220A1 (en) 2017-10-11 2019-04-18 Bioverativ Usa Inc. METHODS FOR INDUCING COMPLEMENT ACTIVITY
MX2020009254A (es) 2018-03-08 2021-01-15 New Atlas Biotechnologies Llc Procesos para la produccion de triptaminas.
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
WO2020018989A1 (en) 2018-07-20 2020-01-23 The Trustees Of Columbia University In The City Of New York Programmable bacteria for the treatment of cancer
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
EP3946626A1 (de) 2019-04-02 2022-02-09 Kenjockety Biotechnology, Inc. Multispezifische antikörper und zusammensetzungen, reagenzien, kits und verfahren dazu
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
MX2022005705A (es) 2019-11-12 2022-08-16 Actym Therapeutics Inc Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
WO2021113736A1 (en) 2019-12-05 2021-06-10 Massachusetts Institute Of Technology Single-domain antibody to chloramphenicol
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CA3182969A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
MX2023001782A (es) 2020-08-12 2023-05-22 Actym Therapeutics Inc Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
EP4429682A2 (de) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunstimulierende bakterien zur umwandlung von makrophagen in einen für eine behandlung geeigneten phänotyp und begleitdiagnostik zur identifizierung von patienten zur behandlung
EP4448007A1 (de) 2021-12-13 2024-10-23 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-abcb1-antikörper
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
US20250195631A1 (en) 2022-03-28 2025-06-19 University Of Massachusetts Antigen delivering salmonella for use as a tumor homing beacon to refocus preexisting, vaccine generated t cells to combat cancer
WO2025128981A1 (en) 2023-12-14 2025-06-19 Sohm, Inc. Compositions and methods for genome editing

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US29043A (en) * 1860-07-10 Improvement in cultivators
JPS57142256A (en) 1981-02-25 1982-09-02 Kao Corp Sanitary napkin
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3486459D1 (de) * 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
CA1321962C (en) 1985-03-20 1993-09-07 Aizo Matsushiro Dental caries preventive preparations and method for preparing said preparations
JPH0696538B2 (ja) 1985-12-19 1994-11-30 株式会社アドバンス 抗発癌剤
JPS62298657A (ja) 1986-06-16 1987-12-25 Diesel Kiki Co Ltd 燃料噴射弁
JPH0761950B2 (ja) 1986-10-17 1995-07-05 塩野義製薬株式会社 抗腫瘍剤
DE3735381A1 (de) 1987-03-31 1989-05-03 Boehringer Mannheim Gmbh Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
JPH01180830A (ja) 1988-01-11 1989-07-18 Kayaku:Kk 抗腫瘍剤
EP0338679A3 (de) 1988-03-24 1991-03-06 Genentech, Inc. Tumor Necrosis Faktor zur Behandlung von Blasenkrebs
JPH0284172A (ja) 1988-07-21 1990-03-26 Smithkline Beckman Corp 異種遺伝子の発現能を有し、組換え型ワクチンとして有用なサルモネラ形質転換体
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
JPH0376580A (ja) * 1989-08-17 1991-04-02 Japan Tobacco Inc 大腸菌発現ベクターとそれを利用した抗ウイルス性タンパク質の製造方法
AU6737190A (en) 1989-11-03 1991-05-31 Washington University Cross-protective salmonella vaccines
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5695983A (en) * 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
CA2097931C (en) * 1990-12-18 2003-07-29 Samuel I. Miller, Iii Salmonella vaccines
EP0574466B1 (de) 1991-03-05 1999-05-19 The Wellcome Foundation Limited Expression rekombinanter proteine in attenuierten bakterien
IL101409A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Method for the early diagnosis of cancer
IL101410A0 (en) 1992-03-29 1992-11-15 Era Masis Ltd Formulation for the treatment of cancer
JPH06298657A (ja) 1993-04-15 1994-10-25 Nippon Shoji Kk 免疫強化剤
TW280772B (de) 1993-08-25 1996-07-11 Otsuka Pharma Factory Inc
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
CA2173495A1 (en) 1993-10-06 1995-04-13 Kenneth W. Culver Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
IT1270123B (it) * 1994-10-05 1997-04-28 Dompe Spa Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US6150170A (en) * 1998-05-03 2000-11-21 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
WO1997008955A1 (en) 1995-09-06 1997-03-13 Department Of The Army, Us Government Bacterial delivery system
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
AU7738396A (en) 1995-11-14 1997-06-05 General Hospital Corporation, The Salmonella secreted proteins and uses thereof
US5997881A (en) 1995-11-22 1999-12-07 University Of Maryland, Baltimore Method of making non-pyrogenic lipopolysaccharide or A
US6887483B2 (en) * 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
WO1997025061A1 (en) * 1996-01-09 1997-07-17 Bristol-Myers Squibb Company De-myristolated lipopolysaccharide of gram-negative bacteria
ES2179295T3 (es) 1996-02-16 2003-01-16 Janssen Pharmaceutica Nv Composiciones que contienen un antifungico y un compuesto de azufre.
US6025417A (en) 1996-02-28 2000-02-15 Biotechnology Research & Development Corp. Biodegradable polyester compositions with natural polymers and articles thereof
ES2188940T3 (es) 1996-05-10 2003-07-01 Upjohn Co Administracion topica de premafloxacina para el tratamiento de enfermedades bacterianas sistemicas.
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
TW373083B (en) 1996-12-20 1999-11-01 Corning Inc Reflective coupling array for optical waveguide
EP0973911A1 (de) 1997-01-30 2000-01-26 Imperial College Of Science, Technology & Medicine MUTIERTE msbB ODER htrB GENE
AU6868198A (en) * 1997-03-28 1998-10-22 Jason C. Grove Antimicrobial mediated bacterial dna delivery
US6537558B2 (en) * 1997-03-31 2003-03-25 Megan Health, Inc. Methods of producing and using virulence attenuated poxR mutant bacteria
US6306387B1 (en) 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
CN1253551C (zh) 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6143551A (en) * 1997-12-29 2000-11-07 Schering Aktiengesellschaft Delivery of polypeptide-encoding plasmid DNA into the cytosol of macrophages by attenuated listeria suicide bacteria
WO1999052563A1 (en) 1998-04-16 1999-10-21 The Regents Of The University Of California A method for the targeting of proteins produced by yersinia into the cytosol of eukaryotic cells
US6004815A (en) 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
US6593592B1 (en) * 1999-01-29 2003-07-15 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device having thin film transistors
EP1261369A4 (de) 1999-10-04 2006-02-01 Vion Pharmaceuticals Inc Verbindungen und methoden zum tumorgerichteten transport von effektormolekülen
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
WO2002020809A1 (en) 2000-09-08 2002-03-14 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP1281767A3 (de) * 2001-07-31 2003-05-28 Aladar A. Szalay Lichtausstrahlende Mikroorganismen und Zellen für die Diagnose und Therapie von Tumoren
US20070298012A1 (en) * 2003-12-16 2007-12-27 Ivan King Compositions and Methods for Tumor-Targeted Delivery of Effector Molecules

Also Published As

Publication number Publication date
ZA988289B (en) 1999-03-22
US6447784B1 (en) 2002-09-10
US20020026655A1 (en) 2002-02-28
DE69841261D1 (de) 2009-12-10
US7514089B2 (en) 2009-04-07
KR20010015577A (ko) 2001-02-26
US20070009489A1 (en) 2007-01-11
US6080849A (en) 2000-06-27
US6923972B2 (en) 2005-08-02
US20030170276A1 (en) 2003-09-11
US6475482B1 (en) 2002-11-05

Similar Documents

Publication Publication Date Title
ATE447005T1 (de) Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
NZ503376A (en) Genetically modified Salmonella sp having a modified msbB gene useful for treating tumours
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
DE69631423D1 (de) Chinolone und deren therapeutische verwendung
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
DK1005353T3 (da) Farmaceutisk præparat omfattende Lactobacillus casei rhamnosus
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
PL314300A1 (en) Peptide-type compounds and their therapeutic application as inhibitors of metalloproteinases
MX9800922A (es) Quinolonas y su uso terapeutico.
DE69427127D1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
BR9805544A (pt) Uso de um composto.
BG102918A (en) Biphenylsulphanomide inhibitors of the matrix metalloproteinase
AU1195499A (en) Thyroxine analogues having no significant hormonal activity to treat malignant tumors
MY133403A (en) Tetracycline derivatives and methods of use thereof
ID21698A (id) Karboksamida-karboksamida aril bisiklik dan penggunaan terapinya
UA66793C2 (uk) Лептин як стримувач швидкого збільшення пухлини клітини
ATE307886T1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
WO2023164455A3 (en) Compositions and methods to modulate the immune system
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
EA200100700A1 (ru) Гены и белки и их применение
SE0100684D0 (sv) New subject-matter
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
DK1294874T3 (da) CD154-varianter og anvendelser deraf
GB9607249D0 (en) Compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties